Chris Molloy, chief executive of the Medicines Discovery Catapult (MDC), discusses its role within the UK as a center for applied medical R&D and the future of the country’s drug discovery profile post-Brexit.
Could you please start by introducing the MDC?
"We believe that the future is going to be populated not just by large companies but also by coalitions of smaller companies. There will be a fundamental change in the structure of the industry and this will change the ways in which drug discovery projects are managed and perceived."
